Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Integrated Global Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

IQVIA TECHNOLOGIES

"Harness technology for a healthier world.

EXPLORE MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety and quality.

COMPLIANCE OVERVIEW
Integrated Global Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2023

READ MORE

Webinar

"Global Consumer Health Trends 2023 Webinar Series

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • Connected Intelligence
  • AI & Machine Learning
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Genomics
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
AI & Machine Learning with a healthcare IQ.

Artificial intelligence is accelerating opportunities. Realizing the benefits for healthcare requires the right expertise. Together, we can solve the problems of today, and drive the breakthroughs of tomorrow.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
Unlock the power of genomic research.

IQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Institute Report
The Use of Medicines in the U.S. 2023
Usage and Spending Trends and Outlook to 2027
May 02, 2023
To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.

Report Summary

As we look back on 2022, the third year of the COVID-19 pandemic, we see areas of greater clarity around the utilization of health services, medicine use, and spending trends, while in other areas — including the impact of the most consequential healthcare reform in more than a decade — greater uncertainty appears to be on the horizon. The U.S. healthcare system remains fragmented, opaque and often dysfunctional, despite the rallying efforts of the pandemic years.

Evidence-based research and dissemination of findings remain a key foundation to advance our collective understanding and interpretation of events, and to take actions that will shape the future for all stakeholders. This annual trend report is intended to contribute to that understanding.

Areas of focus in this year’s report range from looking at health system utilization and its recovery from the pandemic, to how medicine usage patterns have shifted, the complex nature of drug pricing, and the impact of out-of-pocket costs on patients.

While forecasting in this environment is not for the faint of heart, we have laid out our view of the drivers of change in medicine spending over the next five years. This includes the impact of biosimilar introductions affecting the single biggest selling drug in the U.S., and our assessment of the consequences of policy changes already legislated but still unclear and which will take effect in the coming years

Key findings:

  • The U.S. market for medicines grew by 5% in 2022, reaching a total value of $429Bn.
  • Health services utilization reached 100% of pre-pandemic levels for the first time at the end of 2022, up from a low of 66% in Q2 of 2020.
  • Telehealth visits fell to 5% of total vists in 2022, down from peak of 25% early in the pandemic.
  • Biosimilars now account for 25% of total volume of reference molecules prescribed in the U.S.
  • The average patient out-of-pocket cost per retail prescription dropped to $9.38 in 2022, down from $10.15 in 2017.
  • Significant spending growth areas expected over the next five years in oncology, obesity and neuroscience, while total net medicine spending is projected to remain unchanged.

Other findings:

  • The cumulative Health Services Utilization Index across the pandemic (Q2 2020-Q4 2022) remains at 92 despite a recovery in recent quarters to pre-pandemic levels, indicating both concerning gaps in preventive and treatment services that have yet to be addressed and avoided interactions with the healthcare system due to declines in routine illnesses (e.g., flu).
  • Doctor visits — including face-to-face and telehealth — were the least impacted during the pandemic and have remained above pre-pandemic levels since early 2021, however the cumulative index remains 2% below baseline. • Screening and diagnostic tests have remained below baseline throughout the pandemic and declined throughout 2022, likely driven by the declining use of COVID-19 testing in medical settings as testing decreased and at-home testing became more accessible.
  • Screening and diagnostic tests have remained below baseline throughout the pandemic and declined throughout 2022, likely driven by the declining use of COVID-19 testing in medical settings as testing decreased and at-home testing became more accessible.
  • Total prescriptions — adjusted for prescription length — reached 6.7 billion in 2022, up from 6.1 billion in 2018.
  • In total, dispensed prescriptions increased 3.6% in 2022 and had minimal impacts on growth throughout the pandemic.
  • The increasing importance of 90-day prescriptions is evident as the rate of growth without adjustment for prescription length was -0.1% on average over the last five years, but 2.5% after adjustment with 1.1 billion 90-day prescriptions in 2022.
  • Over the past five years, spending at list prices [Wholesaler Acquisition Cost (WAC)] has increased from $600Bn to $858Bn — an average of 7.4% per year.
  • Payer net spending has increased from $461Bn to $603Bn over five years at a compound annual growth rate of 4.5%.
  • Spending at manufacturer net prices, including all products, are estimated to have grown an average of 5.6% over five years.
  • Patient out-of-pocket costs increased $2.1Bn in 2022, exceeding peak levels last seen in 2018.
  • This growth was driven by non-retail out-of-pocket costs, which grew $1.2Bn, or 7.5%, in 2022, returning to pre-pandemic growth rates following a significant decline in 2020.
  • Retail out-of-pocket costs grew $949Mn, or 1.5%, in 2022 and have remained relatively stable over the last five years, growing an average 0.7% annually.
  • Total net spending on medicines in 2027 is expected to be unchanged compared to 2022 as volume growth drivers will be fully offset by drivers of lower prices, including patent expiries and the effects of legislation.
  • Over the next five years, medicine spending will grow between 1–4% on a list price basis and -2 to 1% after discounts and rebates.
  • Growth will be driven by adoption of newly launched innovative products, with an average of 50–55 new medicines launching per year over the next five years, including those in oncology or with specialty or orphan status.

YOU MAY ALSO BE INTERESTED IN

Event
The Use of Medicines in the U.S. 2023
May 18, 2023
Institute Report
The Global Use of Medicines 2022
Institute Report
The Use of Medicines in the U.S. 2022
Institute Report
Optimizing Oncology Care Through Biomarker Adoption
Institute Report
Global Medicine Spending and Usage Trends
Institute Report
Biosimilars in the United States 2020–2024
Blog
"The Hard Slog Will Continue:" Trends in Use and Spending on Medicines in the U.S.
By: Murray Aitken
Prev
Next

Related solutions

Clinical Research & Development Solutions

Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.

Real World Evidence

IQVIA is using vast quantities of data in powerful new ways. See how we can help you tap into information from past trials, patient reported outcomes and other sources to accelerate your research.

Commercialization

Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.

Integrated Global Compliance

Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.

Payers

Greater visibility into the impact of treatments.

Oncology

Bring innovations in oncology treatments to patients, faster

Contact Us